

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**

THIS PAGE BLANK (USPTO)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/34		A1	(11) International Publication Number: WO 97/44027 (43) International Publication Date: 27 November 1997 (27.11.97)
<p>(21) International Application Number: PCT/US97/07985</p> <p>(22) International Filing Date: 13 May 1997 (13.05.97)</p> <p>(30) Priority Data: 60/017,891 17 May 1996 (17.05.96) US 9612065.4 10 June 1996 (10.06.96) GB</p> <p>(71) Applicants (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). MERCK FROSST CANADA INC. [CA/CA]; 16711 Trans Canada Highway, Kirkland, Quebec H9H 3L1 (CA).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): HANCOCK, Bruno [GB/CA]; 16711 Trans Canada Highway, Kirkland, Quebec H9H 3L1 (CA). WINTERS, Conrad [GB/CA]; 16711 Trans Canada Highway, Kirkland, Quebec H9H 3L1 (CA). GERTZ, Barry [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). GOTTESDIENER, Keith [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).</p> <p>(74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).</p>		<p>(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p>	
<p>(54) Title: COMPOSITIONS FOR A ONCE A DAY TREATMENT OF CYCLOOXYGENASE-2 MEDIATED DISEASES</p> <p>(57) Abstract</p> <p>This invention is directed to a pharmaceutical composition for the treatment of cyclooxygenase-2 mediated diseases, said composition being suitable for once a day oral administration, said composition comprising 2.5 to 250 mgs of 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone. The invention is also directed to a method of treating cyclooxygenase-2 mediated diseases comprising the once a day oral administration of 2.5 to 250 mgs of 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone. The invention is also directed to the use of 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone in the manufacture of a medicament containing 2.5 to 250 mgs of said compound for once a day administration for the treatment of cyclooxygenase-2 mediated diseases.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TITLE OF THE INVENTION**COMPOSITIONS FOR A ONCE A DAY TREATMENT OF
CYCLOOXYGENASE-2 MEDIATED DISEASES****5 BACKGROUND OF THE INVENTION**

This invention relates to pharmaceutical compositions for the treatment of cyclooxygenase-2 mediated diseases, methods of treatment thereof and the use of a compound in the manufacture of a medicament.

10 In particular, this invention relates to a pharmaceutical composition for the treatment of cyclooxygenase-2 mediated diseases, said composition being suitable for once a day administration, said composition comprising

15 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5*H*)-furanone.



Non-steroidal anti-inflammatory agents are normally administered 2 to 4 times daily. The relatively short half-life of most non-steroidal anti-inflammatory agents means that once a day administration is impractical and even twice a day administration is unusual. The relatively large doses needed to achieve once a day treatment of conventional non-steroidal anti-inflammatory agents would also lead to side effects so that there is a general understanding that once a day administration is unlikely to be achievable.

20 25 Surprisingly a compound has been identified which can be employed on a once a day basis and which will not produce an

- 2 -

unacceptable level of side effects on such a regimen, and in particular will not cause an unacceptable level of gastric side effects.

US 5,474,995, issued December 12, 1995, WO 95/00501, published January 5, 1995 and WO 95/18799, published July 13, 1995, 5 disclose 3,4-di-substituted furanones and derivatives thereof as potent, selective inhibitors of cyclooxygenase-2. We have found that 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone, possesses a surprising combination of attributes that make it possible to formulate and use the composition in a surprising manner. 10 Not only is the compound potent, safe and effective at modest oral dosages of 2.5 to 250 mg of agent per day, but in addition this active agent possesses a half-life in humans of sufficient length that a single oral dose of 2.5 to 250 mg of agent per day will provide effective safe anti-inflammatory treatment over a 24 hour period. Such active agents 15 are particularly useful in the treatment of chronic indications, including arthritis, pain, Alzheimer's disease and the like.

SUMMARY OF THE INVENTION

This invention is directed to a pharmaceutical composition 20 for the treatment of cyclooxygenase-2 mediated diseases, said composition being suitable for once a day oral administration, said composition comprising 2.5 to 250 mgs of 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone.

The invention is also directed to a method of treating 25 cyclooxygenase-2 mediated diseases comprising the once a day oral administration of 2.5 to 250 mgs of 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone.

The invention is also directed to the use of 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone in the 30 manufacture of a medicament containing 2.5 to 250 mgs of said compound for once a day administration for the treatment of cyclooxygenase-2 mediated diseases.

- 3 -

DETAILED DESCRIPTION OF THE INVENTION

In one embodiment, this invention is directed to a pharmaceutical composition for the treatment of cyclooxygenase-2 mediated diseases, said composition being suitable for once a day oral 5 administration, said composition comprising 2.5 to 250 mg of 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone, and a pharmaceutical carrier therefor.

5,5-Dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone, its utility and methods of 10 making them are disclosed in US 5,474,995, issued December 12, 1995, WO 95/00501, published January 5, 1995 and WO 95/18799, published July 13, 1995, which are hereby incorporated by reference.

As discussed in US 5,474,995 compounds including 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone are useful for the relief of pain, fever and inflammation of a variety of conditions including rheumatic fever, symptoms associated with influenza or other viral infections, common cold, low back and neck pain, dysmenorrhea, headache, toothache, sprains and strains, myositis, neuralgia, synovitis, arthritis, including rheumatoid arthritis 15 degenerative joint diseases (osteoarthritis), gout and ankylosing spondylitis, bursitis, burns, injuries following surgical and dental procedures. In addition, such a compound may inhibit cellular neoplastic transformations and metastatic tumor growth and hence can be used in the treatment of cancer. It is also useful for the treatment of 20 dementia including pre-senile and senile dementia, and in particular, dementia associated with Alzheimer's Disease (ie Alzheimer's dementia).

The compound will also inhibit prostanoid-induced smooth muscle contraction by preventing the synthesis of contractile prostanoids 25 and hence may be of use in the treatment of dysmenorrhea, premature labor and asthma.

By virtue of its potent inhibitory activity against cyclooxygenase-2 (COX-2) and/or its selectivity for inhibiting COX-2 over cyclooxygenase-1 (COX-1) the specified compound is also useful

- 4 -

as an alternative to conventional non-steroidal antiinflammatory drugs (NSAID'S) particularly where such NSAIDS may be contra-indicated such as in patients with peptic ulcers, gastritis, regional enteritis, ulcerative colitis, diverticulitis or with a recurrent history of
5 gastrointestinal lesions; GI bleeding, coagulation disorders including anemia such as hypoprothrombinemia, haemophilia or other bleeding problems (including those relating to reduced or impaired platelet function); kidney disease (eg impaired renal function); those prior to surgery or taking anticoagulants; and those susceptible to NSAID
10 induced asthma.

For the treatment of any of these cyclooxygenase mediated diseases the compound may be administered orally.

As indicated above, pharmaceutical compositions for treating COX-2 mediated diseases as defined may optionally include one
15 or more ingredients as listed above.

The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or
20 elixirs. The compositions are intended for oral use and may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to
25 provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium
30 phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc.

- 5 -

Other suitable formulations are set forth in U.S. Patent No. 5,474,995. However, in view of the unique set of properties possessed by 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5*H*)-furanone, including long half-life, low solubility, high potency and 5 de minimis gastrointestinal (GI) side effects we have found the following oral formulations to be of particular value:

Rapidisc® – In view of the above mentioned characteristics, 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5*H*)-furanone is particularly well suited for a 10 rapid dissolving sublingual formulation. For example, due to the lack of GI side-effects, the agent need not be taken with a large amount of water. Suitable Rapidisc® formulations and methods of making same are disclosed in US 4,305,502, US 4,371,516, US 4,470,202, US 4,758,598, US 4,754,597, US 5,046,618 and US 5,188,882, all of which 15 are hereby incorporated by reference.

As mentioned in the Background section, we have found 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5*H*)-furanone to possess a surprising combination of attributes. Not only are these active agents potent safe and effective at modest oral dosages of 20 2.5 to 250 mg of agent per day, but in addition these active agents possess a half-life in humans of sufficient length that a single oral dose of 2.5 to 250 mg of active agent per day will provide effective safe anti-inflammatory treatment over a 24 hour period. Such agents are particularly useful in the treatment of chronic indications, such as 25 rheumatoid and osteo arthritis as well as Alzheimer's Disease.

Oral dosage levels for agents 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5*H*)-furanone are of the order of from about 2.5 to 250 mg per patient per day.

The amount of active agent that may be combined with the 30 carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a formulation intended for oral administration to humans may contain from 2.5 to 250 mg of agent compounded with an appropriate and convenient amount of carrier material which may vary from about

- 6 -

5 to about 95 percent of the total composition. Dosage unit forms may typically contain 2.5, 5, 10, 12.5, 20, 25, 37.5, 50, 75, 100, 125, 150, 175 or 250 mg of active agent.

It will be understood, however, that the specific dose level
5 for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination and the type and severity of the particular disease undergoing therapy. For many patients, a dosage range of 2.5 to 125 or 10 to 75 mg per day is
10 preferred.

For long term therapy, such as in the treatment of chronic diseases including rheumatoid arthritis, osteoarthritis or Alzheimer's disease, a dosage of 10 to 75 or 5 to 125 mg per day is preferred. More particularly, for the treatment of osteoarthritis, a dosage of 10, 25 or 50
15 mg per day is preferred, whereas for the treatment of rheumatoid arthritis, 25, 50 or 75 mg per day is preferred. For the treatment of non-chronic indications such as headache or post-operative swelling and pain, 5, 10, 25 or 50 mg per day is preferred.

Accordingly, in one aspect this invention is directed to a
20 pharmaceutical composition for the treatment of COX-2 mediated diseases, said composition being suitable for once a day oral administration, said composition comprising a 2.5 to 250 mg of 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone, and a pharmaceutical carried therefor.

25 Within this aspect there is a first genus of compositions comprising 5, 10 or 25 mg of 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone.

Within this aspect there is a second genus of compositions comprising 10 to 125 mg of 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone.

Within this genus there is a class of compositions comprising 10 to 75 mg of 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone.

- 7 -

Within this genus there is a second class of compositions comprising 10, 25, or 50 mg of 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5*H*)-furanone.

Within this genus there is a third class of compositions 5 comprising 25, 50 or 75 mg of 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5*H*)-furanone.

In another aspect the invention is directed to a unit dose oral form which comprises from 5 to 22.5 mg of 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5*H*)-furanone, for 10 example, 12.5 or 20 mg.

EXAMPLE 1

Wet granulated tablet composition

	15	Amount per tablet	Ingredient
20	25 mg	COX-2 Inhibitor	
	79.7 mg	Microcrystalline cellulose	
	79.7 mg	Lactose monohydrate	
	6 mg	Hydroxypropyl cellulose*	
	8 mg	Croscarmellose sodium	
	1 mg	Magnesium stearate	

25 Tablet dose strengths of between 5 and 125 mg can be accommodated by varying total tablet weight, and the ratio of the first three ingredients. Generally it is preferable to maintain a 1:1 ratio for microcrystalline cellulose : lactose monohydrate.

* Klucel®LF® from Aqualon

30

EXAMPLE 1a

Wet granulated tablet composition

	35	Amount per tablet	Ingredient
30	12.5 mg	COX-2 Inhibitor	
	86 mg	Microcrystalline cellulose	
	86 mg	Lactose monohydrate	

- 8 -

6 mg	Hydroxypropyl cellulose
8 mg	Croscarmellose sodium
1 mg	Magnesium stearate

5

EXAMPLE 1b

Wet granulated tablet composition

10	Amount per tablet	Ingredient
	10 mg	COX-2 Inhibitor
	87.2 mg	Microcrystalline cellulose
	87.2 mg	Lactose monohydrate
15	6 mg	Hydroxypropyl cellulose
	8 mg	Croscarmellose sodium
	1 mg	Magnesium stearate

20 **EXAMPLE 1c**

Wet granulated tablet composition

25	Amount per tablet	Ingredient
	5 mg	COX-2 Inhibitor
	89.7 mg	Microcrystalline cellulose
	89.7 mg	Lactose monohydrate
	6 mg	Hydroxypropyl cellulose
30	8 mg	Croscarmellose sodium
	1 mg	Magnesium stearate

EXAMPLE 2

35 **Directly compressed tablet composition**

40	Amount per tablet	Ingredient
	25 mg	COX-2 Inhibitor
	106.9 mg	Microcrystalline cellulose

- 9 -

106.9 mg	Lactose anhydrate
7.5 mg	Croscarmellose sodium
3.7 mg	Magnesium stearate

5 Tablet dose strengths of between 5 and 125 mg can be accommodated by varying total tablet weight, and the ratio of the first three ingredients. Generally it is preferable to maintain a 1:1 ratio for microcrystalline cellulose : lactose monohydrate.

10 **EXAMPLE 2a**

Directly compressed tablet composition

	Amount per tablet	Ingredient
15	12.5 mg	COX-2 Inhibitor
	113.2 mg	Microcrystalline cellulose
	113.2 mg	Lactose anhydrate
	7.5 mg	Croscarmellose sodium
20	3.7 mg	Magnesium stearate

EXAMPLE 2b

Directly compressed tablet composition

	Amount per tablet	Ingredient
25	10 mg	COX-2 Inhibitor
	42.5 mg	Microcrystalline cellulose
	42.5 mg	Lactose anhydrate
	4 mg	Croscarmellose sodium
	1 mg	Magnesium stearate

EXAMPLE 2c

Directly compressed tablet composition

	Amount per tablet	Ingredient
40	5 mg	COX-2 Inhibitor

- 10 -

45 mg	Microcrystalline cellulose
45 mg	Lactose anhydrate
4 mg	Croscarmellose sodium
1 mg	Magnesium stearate

5

EXAMPLE 3

Hard gelatin capsule composition

10 **Amount per capsule Ingredient**

25 mg	COX-2 Inhibitor
37 mg	Microcrystalline cellulose
37 mg	Lactose anhydrate
1 capsule	Hard gelatin capsule
1 mg	Magnesium stearate

15 Capsule dose strengths of between 1 and 50 mg can be accommodated by varying total fill weight, and the ratio of the first three ingredients.

20 Generally it is preferable to maintain a 1:1 ratio for microcrystalline cellulose : lactose monohydrate.

EXAMPLE 4

25

Oral solution

Amount per 5 mL dose Ingredient

30	50 mg COX-2 Inhibitor
	To 5 mL with Polyethylene oxide 400

35 Solution dose strengths of between 1 and 50 mg/5mL can be accommodated by varying the ratio of the two ingredients.

EXAMPLE 5

Oral suspension

40 **Amount per 5 mL dose Ingredient**

- 11 -

	101 mg	COX-2 Inhibitor
	150 mg	Polyvinylpyrrolidone
5	2.5 mg	Poly oxyethylene sorbitan monolaurate
	10 mg	Benzoic acid
	To 5 mL with sorbitol solution (70%)	

Suspension dose strengths of between 1 and 50 mg/5mL can be accomodated by varying the ratio of the first and last ingredients.

10

EXAMPLE 6

Intravenous infusion

	Amount per 200mL dose	Ingredient
15		
	1 mg	COX-2 inhibitor
	0.2 mg	Polyethylene oxide 400
	1.8 mg	Sodium chloride
20	to 200mL	Purified water

STARTING MATERIALS

25 5,5.-Dimethyl-3-(3-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone

Step 1: Methyl 2-trimethylsilyloxyisobutyrate
 To a solution of 1.2 mL (10.4 mmol) of methyl 2-hydroxyisobutyrate in 50 mL of CH_2Cl_2 were added 1.2 g (17.6 mmol) of 30 imidazole and 2.1 mL (16.6 mmol) of TMSCl. The mixture was stirred at r.t. for 1.5 h and quenched with 20 mL of H_2O . The organic layer was dried over MgSO_4 , concentrated and passed through a short plug of silica gel eluted with 9:1 hexane/EtOAc. Evaporation of solvent afforded 1.27 g of the title compound as a colorless oil.

35 ^1H NMR (CD_3COCD_3) δ 0.08 (9H, s), 1.38 (6H, s), 3.67 (3H, s).

Step 2: 2-Trimethylsilyloxy-4'-(methylthio)isobutyrophenone

- 12 -

A solution of 204 mg (1.0 mmol) of 4-bromothioanisole in 2.5 mL of THF was cooled to -78°C and treated with 0.42 mL of 2.5 M n-BuLi solution in hexane. After stirring at -78°C for 1 h, a solution of 380 mg (2.0 mmol) of methyl 2-trimethylsilyloxyisobutyrate (Step 1) in 5 2 mL of THF was added. The mixture was stirred at -78°C for 2 h and then quenched with NH₄OAc buffer. The product was extracted with EtOAc, dried over MgSO₄ and concentrated. The residue was purified by flash chromatography, eluting with 19:1 hexane/EtOAc to give 95 mg of the title product.

10 ¹H NMR (CD₃COCD₃) δ 0.05 (9H, s), 1.52 (6H, s), 2.53 (3H, s), 7.33 (2H, d), 8.12 (2H, d).

Step 3: 2-Hydroxy-4'-(methylthio)isobutyrophenone

To a solution of 40 mg (0.14 mmol) of 2-trimethylsilyloxy-15 4'-(methylthio)isobutyrophenone (Step 2) in 2 mL THF was added 0.2 mL of 1 M n-Bu₄NF in THF. The resulting mixture was stirred for 30 min and then quenched with 10 mL of NH₄OAc buffer. The product was extracted with EtOAc, dried over MgSO₄ and concentrated. The residue was purified by flash chromatography, eluting with 4:1 20 hexane/EtOAc to give 25 mg of the title product.

¹H NMR (CD₃COCD₃) δ 1.50 (6H, s), 2.54 (3H, s), 4.68 (1H, s), 7.30 (2H, d), 8.15 (2H, d).

Step 4 2-hydroxy-4'-(methylsulfonyl)isobutyrophenone

25 To a solution of 2-hydroxy-4'-
(methylthio)isobutyrophenone (Step 3) (45 g) in t-BuOH (500 mL) and CH₂Cl₂ (200 mL) was added a solution of OXONETTM (194 g) in H₂O (1.4 L). The reaction mixture was stirred for 18 h at r.t. and then extracted with EtOAc (3 x 500 mL). The organic extracts were 30 combined and dried over Na₂SO₄ and the solvent was evaporated. The residue was swished in Et₂O/hexane to give the title compound as a yellow solid (47.4 g).

Step 5 3-Fluorophenylacetic acid, 1,1-dimethyl-2-(4-(methylsulfonyl)phenyl)-2-oxo-ethyl ester

35

- 13 -

A mixture of 2-hydroxy-4'-
(methylsulfonyl)isobutyrophenone (Step 4) (100 g), 3-
fluorophenylacetic acid (83 g), 1-cyclohexyl-3-(2-
5 morpholinoethyl)carbodiimide metho-p-toluenesulfonate (225 g) and
DMAP (25 g) in CH₂Cl₂ (2 L) was mechanically stirred for 17 h at r.t..
A solution of 1N HCl (1 L) was then added and the organic phase was
separated, washed with a saturated solution of Na₂CO₃ (0.4 L) and
dried over MgSO₄. After concentration, the residue was purified by
10 silica gel chromatography, eluting with 30% EtOAc/hexane to give the
title compound as a white solid (133 g).

Step 6 5,5-Dimethyl-3-(3-fluorophenyl)-4-(4-
15 (methylsulfonyl)phenyl))-2-(5H)-furanone
A solution of the product from Step 5 (120 g) in CH₂Cl₂ (1
L) was treated with DBU (81.6 g) and stirred for 1 h at r.t.. The
reaction mixture was then treated with 1N HCl (550 mL) and the
organic phase was separated, washed with saturated NaHCO₃ and dried
20 over MgSO₄. After concentration, the crude was swished with 20%
EtOAc/hexane (450 mL), and filtered to give the title compound as a
white solid (108.4 g, m.p. 172.7°C).

Analysis Calculated C 63.32; H 4.75
25 Found: C 63.50; H 4.79

ABBREVIATIONS

DBU = 1,8-diazabicyclo[5.4.0]undec-7-ene
30 DMAP = 4-(dimethylamino)pyridine
OXONETTM = 2KHSO₅.KHSO₄.K₂SO₄
THF = tetrahydrofuran
TLMSCl = trimethylsilyl chloride

- 14 -

WHAT IS CLAIMED IS:

1. A pharmaceutical composition for the treatment of cyclooxygenase-2 mediated diseases, said composition being suitable for 5 once a day oral administration, said composition comprising 2.5 to 250 mg of a compound is 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5*H*)-furanone.
2. A composition according to Claim 1 comprising 10, 10 or 25 mg of 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)-phenyl)-2-(5*H*)-furanone.
3. A composition according to Claim 1 comprising 15 to 125 mg of 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)-phenyl)-2-(5*H*)-furanone.
4. A composition according to Claim 1 comprising 20 to 75 mg of 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)-phenyl)-2-(5*H*)-furanone.
5. A composition according to Claim 1 comprising 25, 25, or 50 mg of 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)-phenyl)-2-(5*H*)-furanone.
6. A composition according to Claim 1 comprising 30 25, 50 or 75 mg of 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)-phenyl)-2-(5*H*)-furanone.
7. A pharmaceutical composition according to Claim 1, 35 2, 3, 4, 5, or 6 further comprising
 - (a) Microcrystalline cellulose,
 - (b) Lactose monohydrate,
 - (c) Hydroxypropyl cellulose,
 - (d) Croscarmellose sodium, and
 - (e) Magnesium stearate; or further comprising

- 15 -

5 (a) Microcrystalline cellulose,
(b) Lactose anhydrate,
(c) Croscarmellose sodium, and
(d) Magnesium stearate; or further comprising

10 Polyethylene oxide 400; or further comprising

15 (a) Sorbitol solution,
(b) Polyvinylpyrrolidone,
(c) Poly oxyethylene sorbitan monolaurate, and
(d) Benzoic acid.

20 8. A method of treating an inflammatory disease
susceptible to treatment with an non-steroidal anti-inflammatory agent
comprising:
administration orally once a day to a patient in need of such treatment
2.5 to 250 mg of 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-
methylsulfonyl)phenyl)-2-(5*H*)-furanone.

25 9. A method according to Claim 8 comprising:
administration orally once a day to a patient in need of such treatment
5, 10 or 25 mg of 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-
methylsulfonyl)phenyl)-2-(5*H*)-furanone.

30 10. A method according to Claim 8 comprising:
administration orally once a day to a patient in need of such treatment
10 to 125 mg of 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-
methylsulfonyl)phenyl)-2-(5*H*)-furanone.

35 11. A method according to Claim 8 comprising:
administration orally once a day to a patient in need of such treatment
10 to 75 mg of 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)-
phenyl)-2-(5*H*)-furanone.

35 12. A method according to Claim 8 comprising:

- 16 -

administration orally once a day to a patient in need of such treatment 10, 25 or 50 mg of 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5*H*)-furanone.

5 13. A method according to Claim 8 comprising:
administration orally once a day to a patient in need of such treatment 25, 50 or 75 mg of 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5*H*)-furanone.

10 14. A method of treating an inflammatory disease susceptible to treatment with a non-steroidal anti-inflammatory agent comprising:
administration orally once a day to a patient in need of such treatment a composition according to Claim 7.

15 15. A method according to Claim 9 for the treatment of non-chronic headache, pain or swelling.

16. A method according to Claim 12 for the treatment of
20 osteoarthritis.

17. A method according to Claim 13 for the treatment of rheumatoid arthritis..

25 18. Use of 2.5 to 250 mg of 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5*H*)-furanone in the manufacture of a once a day oral dosage form of a medicament for the treatment of an inflammatory disease susceptible to treatment with a non-steroidal anti-inflammatory agent.

30 20. Use according to Claim 18 of 5, 10 or 25mg of 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5*H*)-furanone in the manufacture of a once a day oral dosage form of a

- 17 -

medicament for the treatment of an inflammatory disease susceptible to treatment with a non-steroidal anti-inflammatory agent.

21. Use according to Claim 18 of 10 to 125 mg of 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone in the manufacture of a once a day oral dosage form of a medicament for the treatment of an inflammatory disease susceptible to treatment with a non-steroidal anti-inflammatory agent.
- 10 22. Use according to Claim 18 of 10 to 75 mg of 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone in the manufacture of a once a day oral dosage form of a medicament for the treatment of an inflammatory disease susceptible to treatment with a non-steroidal anti-inflammatory agent.
- 15 23. Use according to Claim 18 of 10, 25 or 50 mg of 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone in the manufacture of a once a day oral dosage form of a medicament for the treatment of an inflammatory disease susceptible to treatment with a non-steroidal anti-inflammatory agent.
- 20 24. Use according to Claim 18 of 10, 25 or 50 mg of 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone in the manufacture of a once a day oral dosage form of a medicament for the treatment of osteoarthritis.
- 25 25. Use according to Claim 18 of 25, 50 or 75 mg of 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone in the manufacture of a once a day oral dosage form of a medicament for the treatment of an inflammatory disease susceptible to treatment with a non-steroidal anti-inflammatory agent.
- 30 26. Use according to Claim 18 of 25, 50 or 75 mg of 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5H)-

- 18 -

furanone in the manufacture of a once a day oral dosage form of a medicament for the treatment of rheumatoid arthritis.

27. Use according to Claim 18 of 5, 10 or 25mg of 5,5-
5 dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5*H*)-furanone in the manufacture of a once a day oral dosage form of a medicament for the treatment of non-chronic headache, pain or swelling.

10 28. A unit dose oral form which comprises from 5 to 22.5 mg of dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5*H*)-furanone.

15 29. A unit dosage form according to Claim 28 which comprises 12.5 or 20 mg of dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5*H*)-furanone.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/07985

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 31/34

US CL :514/473

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/473

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS

search terms: cyclooxygenase, furanone, inflammation, antiinflammatory, headache, pain, osteoarthritis, arthritis

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,474,995 A (DUCHARME ET AL) 12 December 1995, column 1, lines 54-56; column 6, line 16; column 63, example 12.	1-29

Further documents are listed in the continuation of Box C. See patent family annex.

A	Special categories of cited documents: document defining the general state of the art which is not considered to be of particular relevance	*T*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
E	earlier document published on or after the international filing date	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
L	document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
O	document referring to an oral disclosure, use, exhibition or other means	*&*	document member of the same patent family
P	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search	Date of mailing of the international search report
16 JULY 1997	12 AUG 1997

Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer WILLIAM JARVIS Telephone No. (703) 308-1235
---	--

THIS PAGE BLANK (USPTO)